专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007147011A2 POLYNUCLEOTIDE THERAPY 审中-公开
标题翻译：多核苷酸治疗
公开(公告)号：WO2007147011A2
公开(公告)日：2007-12-21
申请号：PCT/US2007/071137
申请日：2007-06-13
申请人： BAYHILL THERAPEUTICS, INC. , GARREN, Hideki , LEVITEN, Michael , SOLVASON, Nanette
发明人： GARREN, Hideki , LEVITEN, Michael , SOLVASON, Nanette
IPC分类号： A61K48/00
CPC分类号： C12N15/85 , A61K39/0008 , A61K48/00 , A61K2039/53
摘要： This invention provides methods of treating an autoimmune disease in a subject associated with one or more self-protein(s), polypeptide(s), or peptide(s) present in the subject non-physiologically comprising administering to the subject: a self-vector comprising an immunosuppressive vector backbone and a polynucleotide encoding the self-protein(s), polypeptide(s) or peptide(s) associated with the autoimmune disease; and a divalent cation at a concentration greater than physiological levels. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), polypeptide(s) or peptide(s) modulates an immune response to the self-protein(s), polypeptide(s) or peptide(s) expressed from administration of the self-vector. This invention further provides a method of treating multiple sclerosis by administering a self-vector comprising a BHT-1 vector backbone, for example, self-vector BHT-3009 encoding human myelin basic protein (MBP). The invention also provides a pharmaceutical composition comprising: a BHT-1 vector backbone and a polynucleotide encoding one or more self-protein(s), polypeptide(s), or peptide(s) associated with an autoimmune disease; and a divalent cation at concentrations greater than physiological levels. This invention further provides a pharmaceutical composition comprising a self-vector comprising a BHT-1 vector backbone, for example, self-vector BHT-3009 encoding human myelin basic protein (MBP), and methods of administering a BHT-1 self-vector, for example BHT-3009, to a subject.
摘要翻译：本发明提供了治疗受试者中与存在于受试者中的一种或多种自身蛋白，多肽或多肽相关的受试者的自身免疫性疾病的方法，所述自身蛋白，多肽或肽非生理学上包括对受试者施用：包含免疫抑制载体骨架和编码与自身免疫疾病相关的自身蛋白，多肽或肽的多核苷酸的载体; 和浓度大于生理水平的二价阳离子。施用包含编码自身蛋白，多肽或多肽的多核苷酸的自身载体调节对所表达的自身蛋白，多肽或多肽的免疫应答从自我向量的管理。本发明还提供了通过施用包含BHT-1载体骨架的自身载体，例如编码人髓磷脂碱性蛋白（MBP）的自身载体BHT-3009来治疗多发性硬化症的方法。本发明还提供药物组合物，其包含：BHT-1载体骨架和编码与自身免疫疾病相关的一种或多种自身蛋白质，多肽或肽的多核苷酸; 和浓度大于生理水平的二价阳离子。本发明进一步提供了包含BHT-1载体主链的自身载体的药物组合物，例如编码人髓磷脂碱性蛋白（MBP）的自身载体BHT-3009，以及施用BHT-1自身载体的方法，例如BHT-3009。

2. 发明申请

WO2011091138A1 COMBINATION THERAPY TO TREAT AUTOIMMUNE DISEASES 审中-公开
标题翻译：组合治疗自身免疫性疾病
公开(公告)号：WO2011091138A1
公开(公告)日：2011-07-28
申请号：PCT/US2011/021862
申请日：2011-01-20
申请人： BAYHILL THERAPEUTICS, INC. , LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY , VON HERRATH, Matthias , GARREN, Hideki , SOLVASON, Nanette , LEVITEN, Michael
发明人： VON HERRATH, Matthias , GARREN, Hideki , SOLVASON, Nanette , LEVITEN, Michael
IPC分类号： A61K45/00 , A61K48/00
CPC分类号： A61K45/06
摘要： This invention relates to the treatment of autoimmune diseases with a combination of a B cell specific agent and a DNA antigen specific therapeutic agent encoding a self protein associated with the autoimmune disease. More specifically, the present invention provides a combination of a B cell specific agent, such as an antibody with a DNA antigen specific therapeutic agent, such as a DNA plasmid vector encoding an autoantigen associated the autoimmune disease. Pharmaceutical compositions and articles of manufacture such as kits comprising the agents and combinations thereof are also provided.
摘要翻译：本发明涉及用B细胞特异性试剂与编码与自身免疫性疾病相关的自身蛋白质的DNA抗原特异性治疗剂的组合来治疗自身免疫性疾病。更具体地，本发明提供B细胞特异性试剂，例如抗体与DNA抗原特异性治疗剂的组合，例如编码与自身免疫疾病相关的自身抗原的DNA质粒载体。还提供药物组合物和制品，例如包含试剂及其组合的试剂盒。

3. 发明申请

WO2010151420A1 COMPOSITIONS AND METHODS FOR TREATMENT OF INSULIN-DEPENDENT DIABETES MELLITUS 审中-公开
标题翻译：用于治疗胰岛素依赖性糖尿病的组合物和方法
公开(公告)号：WO2010151420A1
公开(公告)日：2010-12-29
申请号：PCT/US2010/037630
申请日：2010-06-07
申请人： BAYHILL THERAPEUTICS, INC. , GARREN, Hideki , LEVITEN, Michael , SOLVASON, Nanette
发明人： GARREN, Hideki , LEVITEN, Michael , SOLVASON, Nanette
IPC分类号： A61K48/00
CPC分类号： A61K48/0066 , A61K9/0019 , A61K48/005 , A61P3/10 , C07K14/4713 , C07K14/62 , C12N15/86 , C12N2830/001
摘要： This invention provides methods of treating insulin-dependent diabetes mellitus in a subject comprising administering to the subject a self-vector encoding human proinsulin. The invention also provides a pharmaceutical composition comprising a self- vector encoding human proinsulin, as well as treatment and maintenance regimens for administering the pharmaceutical composition to a subject.
摘要翻译：本发明提供了治疗受试者中胰岛素依赖性糖尿病的方法，其包括对受试者施用编码人胰岛素原的自身载体。本发明还提供了包含编码人胰岛素原的自身载体以及用于向受试者施用药物组合物的治疗和维持方案的药物组合物。

4. 发明申请

WO2007147007A2 METHODS AND IMMUNE MODULATORY NUCLEIC ACID COMPOSITIONS FOR PREVENTING AND TREATING DISEASE 审中-公开
标题翻译：用于预防和治疗疾病的方法和免疫调节性核酸组合物
公开(公告)号：WO2007147007A2
公开(公告)日：2007-12-21
申请号：PCT/US2007/071130
申请日：2007-06-13
申请人： BAYHILL THERAPEUTICS, INC. , GARREN, Hideki , LEVITEN, Michael , SOLVASON, Nanette
发明人： GARREN, Hideki , LEVITEN, Michael , SOLVASON, Nanette
IPC分类号： A61K48/00
CPC分类号： A61K31/7084 , A61K31/7088 , C12N15/117 , C12N2310/17 , C12N2310/315 , A61K2300/00
摘要： This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of autoimmune or inflammatory diseases. The invention also relates to the treatment or prevention of disease comprising the administration of the immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-antigen(s), -proteins(s), -polypeptide(s) or -peptide(s). The present invention also relates to methods and compositions for treating diseases in a subject associated with one or more self-antigen(s), self-proteins(s), -polypeptide(s) or -peptide(s) that are present in the subject and involved in a non-physiological state.
摘要翻译：本发明涉及用于治疗或预防疾病的方法和组合物，其包括施用具有一种或多种免疫调节序列（IMS）的免疫调节核酸。本发明还涉及用于鉴定用于预防或治疗疾病的IMS的方法和方法，更具体地涉及治疗和预防自身免疫性或炎性疾病。本发明还涉及治疗或预防疾病，其包括单独施用免疫调节性核酸或与编码自身抗原的多核苷酸， - 蛋白，多肽或 - 肽（ S）。本发明还涉及用于治疗受试者中与一种或多种自身抗原，自身蛋白，多肽或肽存在的疾病相关的疾病的方法和组合物，所述自身抗原，多肽或多肽存在于受试并参与非生理状态。

5. 发明申请

WO2007044394A2 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE DISEASE 审中-公开
标题翻译：用于治疗自身免疫疾病的组合物和方法
公开(公告)号：WO2007044394A2
公开(公告)日：2007-04-19
申请号：PCT/US2006/038776
申请日：2006-10-04
申请人： BAYHILL THERAPEUTICS, INC. , SOLVASON, Nanette , LEVITEN, Michael , GARREN, Hideki
发明人： SOLVASON, Nanette , LEVITEN, Michael , GARREN, Hideki
IPC分类号： A61K48/00
CPC分类号： A61K39/0008 , A61K39/0007 , A61K2039/55561 , A61K2039/55566
摘要： Disclosed are improved methods for the treatment or prevention of an autoimmune disease comprising administration of a modified self-vector encoding and capable of expressing a self-polypeptide that includes one or more pathogenic epitopes associated with the autoimmune disease. The improved method of the present invention includes the administration to a subject of a modified self-vector or self-vectors comprising a polynucleotide encoding a self-polypeptide. In one aspect, the method includes a modified self-vector that allows for increased expression of the self-polypeptide associated with an autoimmune disease in a host cell relative to the unmodified vector. In another, non-mutually exclusive aspect, the method includes a modified self-vector that allows for a secreted autoantigen associated with an autoimmune disease to be encoded as a non-secreted self-polypeptide.
摘要翻译：公开了用于治疗或预防自身免疫疾病的改进方法，包括施用编码并能够表达包含与自身免疫疾病相关的一个或多个病原性表位的自身多肽的修饰的自身载体。本发明的改进方法包括向受试者施用修饰的自身载体或包含编码自身多肽的多核苷酸的自身载体。在一个方面，该方法包括修饰的自身载体，其允许相对于未修饰的载体增加宿主细胞中与自身免疫疾病相关的自身多肽的表达。在另一方面，非相互排斥的方面，该方法包括允许与自身免疫疾病相关的分泌的自身抗原被编码为非分泌的自身多肽的修饰的自身载体。

6. 发明公开

EP2034833A2 POLYNUCLEOTIDE THERAPY 审中-公开
标题翻译：多核苷酸治疗
公开(公告)号：EP2034833A2
公开(公告)日：2009-03-18
申请号：EP07784426.4
申请日：2007-06-13
申请人： Bayhill Therapeutics, Inc.
发明人： GARREN, Hideki , LEVITEN, Michael , SOLVASON, Nanette
IPC分类号： A01N43/04 , A01N63/00 , C12N15/00 , C12N15/63 , C07H21/04
CPC分类号： C12N15/85 , A61K39/0008 , A61K48/00 , A61K2039/53
摘要： This invention provides methods of treating an autoimmune disease in a subject associated with one or more self-protein(s), polypeptide(s), or peptide(s) present in the subject non-physiologically comprising administering to the subject: a self-vector comprising an immunosuppressive vector backbone and a polynucleotide encoding the self-protein(s), polypeptide(s) or peptide(s) associated with the autoimmune disease; and a divalent cation at a concentration greater than physiological levels. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), polypeptide(s) or peptide(s) modulates an immune response to the self-protein(s), polypeptide(s) or peptide(s) expressed from administration of the self-vector. This invention further provides a method of treating multiple sclerosis by administering a self-vector comprising a BHT-1 vector backbone, for example, self-vector BHT-3009 encoding human myelin basic protein (MBP). The invention also provides a pharmaceutical composition comprising: a BHT-1 vector backbone and a polynucleotide encoding one or more self-protein(s), polypeptide(s), or peptide(s) associated with an autoimmune disease; and a divalent cation at concentrations greater than physiological levels. This invention further provides a pharmaceutical composition comprising a self-vector comprising a BHT-1 vector backbone, for example, self-vector BHT-3009 encoding human myelin basic protein (MBP), and methods of administering a BHT-1 self-vector, for example BHT-3009, to a subject.
摘要翻译：本发明提供了治疗与存在于受试者中的一种或多种自身蛋白质，多肽或肽相关的受试者中的自身免疫性疾病的方法，其包括向受试者施用：包含免疫抑制载体骨架和编码与自身免疫疾病相关的自身蛋白，多肽或肽的多核苷酸的载体; 和浓度高于生理水平的二价阳离子。包含编码自身蛋白质，多肽或肽的多核苷酸的自身载体的施用调节对表达的自身蛋白质，多肽或肽的免疫应答，从自我矢量的管理。本发明还提供了通过施用包含BHT-1载体主链，例如编码人髓磷脂碱性蛋白（MBP）的自身载体BHT-3009的自身载体治疗多发性硬化的方法。本发明还提供了药物组合物，其包含：BHT-1载体骨架和编码与自身免疫性疾病相关的一种或多种自身蛋白质，多肽或肽的多核苷酸; 和浓度高于生理水平的二价阳离子。本发明进一步提供了一种药物组合物，其包含含有BHT-1载体主链，例如编码人髓磷脂碱性蛋白（MBP）的自身载体BHT-3009的自身载体和施用BHT-1自身载体的方法，例如BHT-3009，给受试者。

7. 发明公开

EP2032144A2 METHODS AND IMMUNE MODULATORY NUCLEIC ACID COMPOSITIONS FOR PREVENTING AND TREATING DISEASE 审中-公开
标题翻译：程序和免疫调节化合物NUCLEIC用于预防和疾病治疗
公开(公告)号：EP2032144A2
公开(公告)日：2009-03-11
申请号：EP07798517.4
申请日：2007-06-13
申请人： Bayhill Therapeutics, Inc.
发明人： GARREN, Hideki , LEVITEN, Michael , SOLVASON, Nanette
IPC分类号： A61K31/70
CPC分类号： A61K31/7084 , A61K31/7088 , C12N15/117 , C12N2310/17 , C12N2310/315 , A61K2300/00
摘要： This invention relates to methods and compositions for treating or preventing disease comprising the administration of immune modulatory nucleic acids having one or more immune modulatory sequences (IMSs). The invention further relates to the means and methods for the identification of the IMSs for preventing or treating disease, more particularly the treatment and prevention of autoimmune or inflammatory diseases. The invention also relates to the treatment or prevention of disease comprising the administration of the immune modulatory nucleic acids alone or in combination with a polynucleotide encoding self-antigen(s), -proteins(s), -polypeptide(s) or -peptide(s). The present invention also relates to methods and compositions for treating diseases in a subject associated with one or more self-antigen(s), self-proteins(s), -polypeptide(s) or -peptide(s) that are present in the subject and involved in a non-physiological state.

8. 发明公开

EP1931390A2 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE DISEASE 有权
标题翻译：组合物及法治疗自身免疫性疾病
公开(公告)号：EP1931390A2
公开(公告)日：2008-06-18
申请号：EP06825440.8
申请日：2006-10-04
申请人： Bayhill Therapeutics, Inc.
发明人： SOLVASON, Nanette , LEVITEN, Michael , GARREN, Hideki
IPC分类号： A61K48/00 , C12N15/63
CPC分类号： A61K39/0008 , A61K39/0007 , A61K2039/55561 , A61K2039/55566
摘要： Disclosed are improved methods for the treatment or prevention of an autoimmune disease comprising administration of a modified self-vector encoding and capable of expressing a self-polypeptide that includes one or more pathogenic epitopes associated with the autoimmune disease. The improved method of the present invention includes the administration to a subject of a modified self-vector or self-vectors comprising a polynucleotide encoding a self-polypeptide. In one aspect, the method includes a modified self-vector that allows for increased expression of the self-polypeptide associated with an autoimmune disease in a host cell relative to the unmodified vector. In another, non-mutually exclusive aspect, the method includes a modified self-vector that allows for a secreted autoantigen associated with an autoimmune disease to be encoded as a non-secreted self-polypeptide.

9. 发明公开

EP2525825A1 COMBINATION THERAPY TO TREAT AUTOIMMUNE DISEASES 审中-公开
标题翻译：联合治疗自身免疫性疾病的治疗
公开(公告)号：EP2525825A1
公开(公告)日：2012-11-28
申请号：EP11735172.6
申请日：2011-01-20
申请人： Bayhill Therapeutics, Inc. , La Jolla Institute for Allergy and Immunology
发明人： VON HERRATH, Matthias , GARREN, Hideki , SOLVASON, Nanette , LEVITEN, Michael
IPC分类号： A61K45/00 , A61K48/00
CPC分类号： A61K45/06
摘要： This invention relates to the treatment of autoimmune diseases with a combination of a B cell specific agent and a DNA antigen specific therapeutic agent encoding a self protein associated with the autoimmune disease. More specifically, the present invention provides a combination of a B cell specific agent, such as an antibody with a DNA antigen specific therapeutic agent, such as a DNA plasmid vector encoding an autoantigen associated the autoimmune disease. Pharmaceutical compositions and articles of manufacture such as kits comprising the agents and combinations thereof are also provided.

10. 发明授权

EP1931390B1 COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE DISEASE 有权
标题翻译：组合物及法治疗自身免疫性疾病
公开(公告)号：EP1931390B1
公开(公告)日：2012-07-25
申请号：EP06825440.8
申请日：2006-10-04
申请人： Bayhill Therapeutics, Inc.
发明人： SOLVASON, Nanette , LEVITEN, Michael , GARREN, Hideki
IPC分类号： A61K39/00
CPC分类号： A61K39/0008 , A61K39/0007 , A61K2039/55561 , A61K2039/55566
摘要： Disclosed are improved methods for the treatment or prevention of an autoimmune disease comprising administration of a modified self-vector encoding and capable of expressing a self-polypeptide that includes one or more pathogenic epitopes associated with the autoimmune disease. The improved method of the present invention includes the administration to a subject of a modified self-vector or self-vectors comprising a polynucleotide encoding a self-polypeptide. In one aspect, the method includes a modified self-vector that allows for increased expression of the self-polypeptide associated with an autoimmune disease in a host cell relative to the unmodified vector. In another, non-mutually exclusive aspect, the method includes a modified self-vector that allows for a secreted autoantigen associated with an autoimmune disease to be encoded as a non-secreted self-polypeptide.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式